Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0025-7125(16)33421-6 | DOI Listing |
BMC Pulm Med
August 2024
Department of Radiology, Health Sciences University, Adana City Training and Research Hospital, Adana, Türkiye.
Background: Progressive pulmonary fibrosis is the symptomatic, physiological, and radiological progression of interstitial lung diseases. The aim of this study was to examine the relationship between progressive pulmonary fibrosis and demographic characteristics and to evaluate the effect on clinical outcomes and mortality.
Methods: This cross-sectional study included 221 patients diagnosed with non-idiopathic pulmonary fibrosis interstitial lung diseases who were followed in the last 5 years.
Circ Cardiovasc Qual Outcomes
July 2024
Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (M.W.K.).
Background: Cardiogenic shock is a morbid complication of heart disease that claims the lives of more than 1 in 3 patients presenting with this syndrome. Supporting a unique collaboration across clinical specialties, federal regulators, payors, and industry, the American Heart Association volunteers and staff have launched a quality improvement registry to better understand the clinical manifestations of shock phenotypes, and to benchmark the management patterns, and outcomes of patients presenting with cardiogenic shock to hospitals across the United States.
Methods: Participating hospitals will enroll consecutive hospitalized patients with cardiogenic shock, regardless of etiology or severity.
Allergol Select
May 2024
Laboratory Dr. Wisplinghoff.
Respir Investig
January 2024
Department of Pathology Informatics, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!